Teleflex (TFX) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2025, Teleflex (TFX) reported revenue of $913.02 million, up 19.5% over the same period last year. EPS came in at $3.67, compared to $3.49 in the year-ago quarter.The reported revenue represents a surprise of +2.18% over the Zacks Consensus Estimate of $893.51 million. With the consensus EPS estimate being $3.38, the EPS surprise was +8.58%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic Revenues- Americas: $555.9 million versus the seven-analyst average estimate of $543.56 million. The reported number represents a year-over-year change of +28.3%.Geographic Revenues- Asia: $122.9 million versus the seven-analyst average estimate of $129.91 million. The reported number represents a year-over-year change of +25%.Geographic Revenues- EMEA: $234.2 million versus the seven-analyst average estimate of $173.81 million. The reported number represents a year-over-year change of +55.9%.Net Revenues- Interventional: $266.4 million versus the 12-analyst average estimate of $259.79 million. The reported number represents a year-over-year change of +77.7%.Net Revenues- Interventional Urology: $71.8 million compared to the $78.36 million average estimate based on 12 analysts. The reported number represents a change of -13.9% year over year.Net Revenues- OEM: $80.4 million versus $81.73 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.Net Revenues- Vascular Access: $191 million versus the 12-analyst average estimate of $188.37 million. The reported number represents a year-over-year change of +5.6%.Net Revenues- Anesthesia: $101.4 million versus the 12-analyst average estimate of $100.37 million. The reported number represents a year-over-year change of +0.3%.Net Revenues- Other: $79.1 million compared to the $59.36 million average estimate based on 12 analysts. The reported number represents a change of +44.3% year over year.Net Revenues- Surgical: $122.9 million versus the 12-analyst average estimate of $117.34 million. The reported number represents a year-over-year change of +10%.View all Key Company Metrics for Teleflex here>>>Shares of Teleflex have returned -2.9% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teleflex Incorporated (TFX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks